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Background: Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disorder and the leading cause of sudden 
cardiac death in the young. Although in a majority of HCM cases there are gene mutations coding for sarcomere proteins, the onset for 
the clinical consequences of these mutations are difficult to predict, as these mutations do not show any clear relationship to the degree of 
myocardial hypertrophy. Hence identification of early markers for this disease is important. The aim of this study was to investigate novel 
serum biomarkers reflecting myocardial remodeling, microfibrosis and coronary endotheliopathy in young presymtomatic HCM patients and 
in individuals at risk for developing HCM.
methods: Eighty-nine participants (18 HCM patients, 14 HCM-risk individuals, and 57 healthy controls) with median age of 15 (range 
0-30) years underwent assessment with echocardiography and serum analysis for myostatin, cathepsin S, endostatin, type I collagen 
degradation marker (ICTP), matrix metalloproteinase (MMP) 9, vascular (VCAM) and intercellular adhesion molecules (ICAM). In some 
individuals, myocardial perfusion was measured both at rest and after adenosine via magnetic resonance.
results:  Both cathepsin S and endostatin were increased in the HCM group (p<0.05) vs HCM-risk and control groups, and showed weak 
correlation to left ventricular mass (LVM; p<0.001; r>0.3) and diastolic function, expressed as E/e´ (p<0.01; r>0.3). In the HCM-risk group, 
myostatin was decreased (p<0.05), whereas ICAM was increased compared to the other groups (p<0.05). ICAM correlated with adenosine-
induced myocardial perfusion (p=0.04, r=0.4). No differences in ICTP, MMP9 and VCAM were observed between the groups (p>0.1).
conclusion:  To the best of our knowledge, this is the first study to suggest early onset changes in biomarkers of myoblast regulation, 
endothelial function and matrix remodeling in young presymptomatic HCM patients and in HCM-risk individuals.
